Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23696157 | 0.87 | PIK3CD (0.37) | PIK3CDHRH3 | |
| SCHEMBL22848927 | 0.86 | PIK3CD (0.35) | PIK3CDHRH3 | |
| SCHEMBL23696216 | 0.85 | ACHE (0.33) | PIK3CDHRH3 | |
| SCHEMBL23945766 | 0.83 | PIK3CD (0.35) | PIK3CDHRH3 | |
| SCHEMBL22837633 | 0.82 | SMN1; SMN2 (0.36) | HRH3 | |
| SCHEMBL23696289 | 0.81 | GNAO1 (0.36) | — | |
| SCHEMBL22837793 | 0.81 | DRD2 (0.39) | — | |
| SCHEMBL18756129 | 0.80 | PIK3CD (0.38) | PIK3CDHRH3 | |
| SCHEMBL25701277 | 0.79 | HRH3 (0.40) | HRH3 | |
| SCHEMBL21105877 | 0.79 | PIK3CD (0.33) | PIK3CDHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | PIK3CD 421/4885HRH3 3945/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885HRH3 3631/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | PIK3CD 2719/4885HRH3 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.